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BPRS/BPRS-E Brief Psychiatric Rating Scale Expanded 
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Edition
ECT   Electro Convulsive Therapy 
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FTMS/ftms  Failure To Maintain Set from the WCST 
fMRI   functional Magnetic Resonance Imaging 
GAF    Global Assessment of Functioning scale (DSM-IV) 
HDRS    Hamilton Depression Rating Scale
HPA   Hypothalamic-Pituitary-Adrenal  
ICC   Intra-Class Correlation 
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LDFR   Long Delay Free Recall from the CVLT 
LGP   Level of General Psychopathology 
MADRS   Montgomery-Åsberg Depression Rating Scale 
MDD   Major Depressive Disorder 
PANSS  Positive And Negative Syndrome Scale 
PANSS-G   General psychopathology subscale from the PANSS 
PASAT  Paced Auditory Serial Addition Test 
pasat2   2-seconds inter-stimulus interval subtest from the PASAT 
pasat3   3- seconds inter-stimulus interval subtest from the PASAT 
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PET   Positron Emission Tomography 
perserr   perseverative errors from the WCST 
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SCID-I  Structured Clinical Interview for DSM-IV Axis I Disorders 
SD/S.D./s   Standard Deviation 
SeqRT1  Sequential Reaction Time 1 from the CalCAP 
SeqRT2  Sequential Reaction Time 2 from the CalCAP 
SIM   Similarities subtest from the WAIS-R 
SiRT   Simple Reaction Time test from the CalCAP 
SSRIs   Selective Serotonin Re-uptake Inhibitors 
Stroop   Stroop Colour and Word Test 
Stroop c-w/STROCW Colour-Word subtask from the Stroop 
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ToL/tol  Tower of London test 
VSVT    Victoria Symptom Validity Test 
WAIS-R  Wechsler Adult Intelligence Scale-Revised 
WCST   Wisconsin Card Sorting Test 
WHO   World Health Organisation 
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Summary 
Background 
Unipolar major depression is a prevalent disorder and is in the World Health 
Organisation’s (WHO) top five on their global burden of disease-list. For more than 
three decades, assessment of neurocognitive functioning in patients with mental 
disorders by use of neuropsychological tests has been performed for research purposes. 
Patients with schizophrenia have been extensively studied, but a substantial amount of 
research has also been performed on depressed patients.  
 
In patients with unipolar major depression, performance below that of healthy controls 
has been shown on tests measuring memory, attention, psychomotor speed and 
executive functions. Executive Functions (EF) are higher order neurocognitive 
functions that control and integrate other neurocognitive functions; dysfunctions have 
been associated with frontal lobe dysfunction. Still, there is a lack of studies 
investigating EF in the most prevalent form of unipolar major depression, patients with 
recurrent subtype.  
 
This thesis is based on four original research papers published in referee based 
international journals. In paper I, we question whether executive dysfunctions also are 
present in patients with recurrent unipolar major depression compared to healthy 
controls. The investigation includes pattern and severity of executive dysfunction. In 
paper II, we consider whether all patients with recurrent unipolar major depression 
have impairment of EF. Mental disorders can be regarded as both categorical and 
dimensional conditions: according to the continuum model unipolar major depression 
and schizophrenia can be viewed as different levels of general psychopathology (LGP). 
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Paper III explores the continuum model of mental disorders. We investigate whether 
LGP explains more of the variance in EF than diagnosis (unipolar major depression 
versus schizophrenia). Elevated levels of the stress hormone cortisol are often found 
among depressed patients, and there is evidence that prolonged hypercortisolemia can 
be neurotoxic. Specifically, recurrent depression episodes may lead to progressive 
brain damage. It is uncertain if executive dysfunctions in recurrent unipolar major 
depression are associated with elevated cortisol levels. Therefore, the aim of paper IV 
was to explore whether level of saliva cortisol is correlated with level of executive 
dysfunctions in recurrent unipolar major depression. 
 
Method 
Data were collected in the context of a Norwegian, cross-sectional, multi-centre study, 
the BOP, starting in 1998. In the BOP, patients with either a diagnosis of unipolar 
major depressive disorder (MDD), recurrent type (N=50) or schizophrenia (N=53) and 
healthy controls (N=50) were included. The patients were diagnosed by the Structured 
Clinical Interview for DSM-IV Axis I Disorders. Depressed patients scoring above 18 
points on both the Hamilton Depression Rating Scale and Montgomery-Åsberg 
Depression Rating Scale were included. Other inclusion criteria were: age between 20 
and 50, Norwegian language and normal vision and hearing. Patients were excluded if 
they had a history of head trauma, neurological disorder or developmental dysfunction, 
present alcohol or substance abuse, other medical conditions likely to affect 
neurocognitive functions or if they recently had received electro convulsive treatment. 
The clinical psychiatric evaluation was performed by five trained psychiatrists. In the 
BOP, a broad neuropsychological test battery was used to measure several domains of 
neurocognitive function. In this thesis, mainly tests assessing components of EF are 
used. The tests were administered by a licensed clinical neuropsychologists, a graduate 
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psychology student or a medical doctor (Kirsten Irene Stordal) supervised by a 
neuropsychologists. 
 
Results 
There was a tendency for patients with recurrent MDD to perform below healthy 
controls on all measures of EF (Paper I). A significant group difference was found for 
eight of ten measures. The executive dysfunctions were within -1.0 SD from the mean 
of the control group. While the components verbal fluency, inhibition, set-maintenance 
and working memory were affected in recurrent MDD, set-shifting and planning 
seemed to be spared. Whether this dysfunction could be found in all patients with 
recurrent episodes of depression, was uncertain. This was explored in the following 
paper, the result being that more than half of the patients with recurrent MDD had 
unimpaired EF when unimpairment was defined as performance above -1.0 SD of the 
sample mean of the control group on more than one component of EF (Paper II). The 
sub-group of patients without impairment of EF was characterised by higher 
intellectual abilities and fewer episodes of depression than the subgroup with EF 
impairment. In paper III we found EF impairment to be more strongly related to LGP 
than to diagnosis (MDD versus schizophrenia). In the last paper an inverse correlation 
between saliva cortisol and EF was found (Paper IV).  
 
Discussion 
All the papers add to current knowledge in this field: The first paper in that patients 
with recurrent MDD have mild executive dysfunctions, and that seemingly all 
components of EF are affected. The second paper shows that more than half of patients 
with recurrent MDD have unimpaired EF when depressed, and that this subgroup has 
higher intellectual abilities and a history of fewer depression episodes. The novel 
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finding in the third paper is that EF impairment is more strongly related to LGP than 
diagnosis (comparing MDD and schizophrenia). This finding is in line with the 
continuum hypothesis in psychiatry. In recurrent MDD, the level of performance on 
tests assessing EF seems to be inversely correlated with the level of saliva cortisol. 
Thus, this fourth study directly and indirectly gave support to the cortisol hypothesis.   
     
There is little evidence that unipolar major depression is uniquely associated with 
executive dysfunctions due to that 1) most components of EF are affected, 2) not all 
patients have executive dysfunctions, 3) executive dysfunctions are not specific to 
depression as they are also found in other mental disorders and in somatic disorders 
and 4) not all depressed patients have elevated levels of cortisol associated with 
executive dysfunctions. Future studies of the association between mental disorders and 
neurocognitive dysfunction should avoid restrictions resulting from imperfect 
diagnostic classifications for mental disorders, i.e. focusing on similarities in 
neurocognitive dysfunctions across psychiatric diagnoses rather than within one mental 
disorder at the time.      
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Introduction 
Neuropsychological studies of patients with depression have been performed for 
several decades, and the first paper reviewing neurocognitive deficits associated with 
depression was published in 1975 (Miller, 1975). Today, a substantial amount of 
neurocognitive research has been performed on patients with depression, but still there 
are several unanswered questions. The present thesis will attempt to answer a selection 
of these questions relating to the neurocognitive domain of EF in patients with 
recurrent unipolar major depression. 
   
This thesis is based on four original research papers published in referee based 
international journals. The thesis is organised into five main sections. First in the 
introduction section, the epidemiology and clinical characteristics of unipolar major 
depression is presented. Thereafter, literature that is mainly from the period that this 
study was planned and data were collected regarding the association between 
neurocognitive function with a special focus on EF and unipolar major depression is 
summed up. A subsection follows concerning whether mental disorders are categorical 
or dimensional conditions. Finally in the introduction section, the neurobiology of 
unipolar major depression is presented with a focus on models of the pathogenesis of 
recurrent depression and executive dysfunctions. The next section clarifies the main 
aim and sub-aims of the present study. In the material and methods section, the study 
design, the samples and the psychiatric, neuropsychological and cortisol measurements 
are presented as well as the statistical analyses used. In addition, relevant ethical 
aspects of the study are presented. In the results section, summaries of the results from 
the four papers are given. In the last section of the thesis, a synopsis of results is given 
along with a discussion of these results in light of previous findings including updated 
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literature. The idea of presenting “older” literature in the introduction and updated 
literature in the discussion is to illustrate the continued development within these areas 
since publication of the papers. Before discussing general methodological issues 
relevant to the present study, this section approaches possible functional consequences 
of executive dysfunctions for depressed patients and the underlying pathogenesis of 
executive dysfunctions. Thereafter is included the conclusions of the study and their 
clinical implications. Finally, suggestions for future research are given.  
 
The literature search mainly used the PubMed/Medline, PsycINFO and EMBASE 
databases. The search terms were cognition, neuropsychology, neurocognition, EF, 
depression, major depression, unipolar major depression, MDD, recurrent depression, 
cortisol and saliva cortisol. The literature used for the main aims for the most part 
included clinical studies, but also meta-analyses and review papers when they were 
available. The clinical studies selected were so because they were either the best or the 
newest or because the method (the neuropsychological tests or operationalisation), the 
sample or the design was most similar to the present study.         
 
Unipolar major depression 
Mental illness is by WHO defined as absence of good mental health. Epidemiological 
studies have repeatedly found a 12-month prevalence of mental disorders of 
approximately 30 % and lifetime prevalence about 50 % (Kessler et al., 2005, Kringlen 
et al., 2001). Among the 10 leading causes of disability worldwide, five of them are 
mental disorders (Lopez and Murray, 1998). The mental disorder associated with the 
highest disability rate is unipolar major depression followed by alcohol abuse, bipolar 
disorders, schizophrenia and obsessive-compulsive disorders. Epidemiological studies 
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suggest that mental disorder is the single leading cause of permanent work-related 
disability in Norway (Mykletun and Øverland, 2006, Mykletun et al., 2006, Sivertsen 
et al., 2006).  
 
Today, unipolar major depression is rated as the fourth most important contributor to 
the global burden of disease, and the WHO predicts that it will become the second 
largest cause of disability by the year of 2020 after ischemic heart disease (Lopez and 
Murray, 1998). A 12-month prevalence of 6.6 % and a life-time prevalence of 16.2 % 
were recently found according to DSM-IV criteria for Major Depressive Disorder 
(MDD) (Kessler et al., 2003). In comparison, the lifetime prevalence of non-affective 
psychoses including schizophrenia ranges from 0.4 % to 0.7 % (Kringlen et al., 2001, 
Kessler et al., 2005). The point-prevalence of depression has been shown to be stabile 
over a period of 40 years, only slightly increasing in women below 45 years (Murphy 
et al., 2000). Women seem to experience major depression about twice as often as 
men, both in 12-month and lifetime perspectives (Kringlen et al., 2001, Kessler et al., 
1994, Kessler et al., 2003). MDD co-occurs with both somatic as well as other mental 
disorders. Three fourths of patients with lifetime MDD also met the criteria of at least 
one other DSM-IV disorder compared to two thirds of patients with 12-months MDD, 
and the most commonly occurring co-morbid disorders are anxiety disorders, substance 
abuse disorders and impulse control disorders (Kessler et al., 2003). 
 
For the individual, major depression is a serious condition generally associated with 
high risk of psychosocial impairment (Angst, 1999, Judd et al., 2000), reduced quality 
of life (Isacson et al., 2005) and increased mortality and risk of suicide (Blair-West et 
al., 1999, Cuijpers and Smit, 2002). In many respects major depression should be 
regarded as a chronic and life-threatening disorder (Angst, 1999, Cuijpers and Smit, 
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2002). Major depression has extensive medical, social and economic effects and costs 
for society. The impaired work capacity of depressed people leads to a loss of 
productivity that has been suggested to exceed the costs of effective treatment of major 
depression (Wang et al., 2004).  
 
All levels of depressive symptomatology can be found in the population. The 
symptoms range from none to mild, to subtreshold levels of major depression, to major 
depression, and it has been shown that many patients with subtreshold major 
depression receive treatment in the community (Angst and Merikangas, 1997). 
Diagnosis of MDD is based on anamnestic information and observation of clinical 
characteristics, not on evidence of underlying neurobiological pathology. MDD is also 
known as major depression, clinical depression or unipolar major depression (including 
only depressed mood and not the opposite pole of hypomania/mania as in bipolar 
disorders). MDD includes both single episode and recurrent episodes of unipolar major 
depression. The core symptoms of MDD are those involving disturbances of mood and 
affect. According to the fourth edition of the Diagnostic and Statistical Manual of 
Mental Disorders for Axis-I Disorders (DSM-IV) the diagnosis of a major depressive 
episode involves the presence of five or more of these listed symptoms for a period of 
at least two weeks: depressed mood, markedly diminished interest or pleasure, feelings 
of worthlessness or guilt, diminished ability to think or concentrate, recurrent thoughts 
of death or suicide, or various somatic symptoms such as weight loss/gain or 
decreased/increased appetite, insomnia/hypersomnia, psychomotor 
agitation/retardation and fatigue or loss of energy (American Psychiatric Association, 
1994). Either depressed mood or diminished interest should at least be present. To 
qualify for recurrent MDD the patients must have had a minimum of two depression 
episodes with an interval of at least two consecutive months where the criteria of a 
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MDD is not fulfilled. MDD can be treated either with psychotherapy, pharmacotherapy 
or preferably both (Kaplan et al., 1994, Bauer et al., 2002a, Bauer et al., 2002b). The 
characteristic symptoms in schizophrenia are delusions, hallucinations, incoherent 
speech, blunted/flat/inappropriate affect, catatonic behaviour and negative symptoms 
(American Psychiatric Association, 1994). In order to diagnose schizophrenia 
according to the DSM-IV, six criteria must be met. Today, schizophrenia is mainly 
treated with newer antipsychotic medication in the western world (Marder, 2000).  
 
Neuropsychological research has for more than three decades resulted in a view of 
neurocognitive dysfunction as a core feature in both MDD and schizophrenia; 
especially in schizophrenia (Austin et al., 2001, Green, 1998). Dysfunction may have 
negative consequences for the patients’ general functioning and ability to cope 
occupationally (Austin et al., 2001, McCall and Dunn, 2003). Still, there are several 
unanswered questions with regard to the association between MDD and neurocognitive 
functions, in particular regarding recurrent MDD and EF. 
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Recurrent episodes  
The majority of patients suffering from MDD will experience recurrent episodes of 
depression. It is therefore important to achieve greater insight into the association 
between recurrent MDD and neurocognitive function. MDD is a remitting though 
recurring disease. The likelihood of recurrence is higher than 50 % and the occurrence 
of a first episode of depression, especially if the episode is long, increases the risk of 
future episodes (Angst, 1999). Long-term estimates of recurrence have been as high as 
85 % for patients with an episode of major depression and 58 % for patients who 
remained well for 5 years (Mueller et al., 1999). These risk factors for recurrence have 
been suggested: female sex, a lengthy index episode, several prior depression episodes 
and that the person has never been married (Mueller et al., 1999). Other predictors of 
recurrent episodes are psychosocial factors, loss events, previous hospitalisation and 
late-onset depression (Angst, 1999). The symptoms or subtypes have been shown to be 
highly variable from episode to episode in recurrent MDD (Oquendo et al., 2004). It 
has been reported that recurrently depressed patients often receive antidepressant 
treatment below levels shown effective in maintenance therapy; a prolonged treatment 
with effective levels of antidepressant treatment has been recommended to prevent or 
postpone recurrence of episodes (Mueller et al., 1999, Young, 2001). An increased 
understanding of how recurrent MDD and neurocognitive functions are related may 
improve preventive and therapeutic interventions for this subgroup of patients. 
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Neurocognitive function in unipolar major depression  
Cognition, neuropsychology and mental disorders 
Cognition can be defined as “the information-handling aspect of behaviour” (Lezak, 
1995). While cognitive psychology focuses on the human information processes 
associated with normal function, neuropsychology is engaged in the behavioural 
expressions of brain dysfunction in both neurological and non-neurological disorders 
(Lezak, 1995, Lundh et al., 1996, Stuss and Levine, 2002). In patients with psychiatric 
symptoms, neuropsychological testing can be used in order to reveal possible 
underlying brain damage or neurological disorder causing the symptoms, or it can 
measure type and degree of neurocognitive dysfunction in patients with a known 
mental disorder (Howieson and Lezak, 1992).  
 
The discipline of neuropsychology can be divided into clinical neuropsychology and 
experimental neuropsychology. Clinical neuropsychology engages in the clinical 
application of knowledge of brain-behaviour associations for diagnostic, treatment and 
rehabilitation purposes (Lezak, 1995). An important part of the evaluation is the 
neuropsychological testing that often includes both pencil and paper tests as well as 
computerised tests. The neuropsychological assessment of adults relies on comparisons 
between the patient’s present level of functioning and the known or estimated level of 
premorbid functioning as well as on a comparison of inter-subjective results across a 
wide range of neuropsychological tests (Lezak, 1995). In clinical research, significance 
testing is most often used to detect differences between groups of subjects (Lezak, 
1995, Zakzanis et al., 1999).  
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Historically, the localisation of brain functions has been central in neuropsychology 
(Stuss and Levine, 2002). Neuropsychological assessment is more a description of 
behaviour and a measure of functioning, and neuroimaging techniques are commonly 
used to identify functional brain abnormalities associated with major depression and 
schizophrenia. More recent neuroimaging studies often include an assessment of 
neuropsychological function (Austin et al., 2001, Elliott, 2002). So, it can be argued 
that localisation of neurocognitive functions has been actualised in recent clinical 
research linking behavioural data and neuroimaging evidence.  
Neurocognitive function in unipolar major depression 
To the experienced clinician, it is well known that depressed patients often complain of 
difficulties concentrating and remembering. A diminished ability to concentrate is also 
included as a key symptom in the diagnostic classification of a major depressive 
episode in the DSM-IV and is an integral component of some depression scales, i.e. the 
Montgomery and Åsberg Depression Rating Scale (MADRS) (Montgomery and 
Åsberg, 1979).  
 
It is now widely accepted that major depression is associated with deficits in a range of 
neurocognitive domains (Austin et al., 2001, Elliott, 2002, Veiel, 1997). During the last 
two decades, studies have investigated neurocognitive deficits of different clinical 
subgroups of patients with major depression and impairment has been reported in 
attention (Landrø et al., 2001b, Mialet et al., 1996, Porter et al., 2003, Zakzanis et al., 
1999), memory (Austin et al., 2001, Landrø et al., 1997, Veiel, 1997, Zakzanis et al., 
1999), psychomotor functions (Degl’Innocenti et al., 1998, Mialet et al., 1996, 
Zakzanis et al., 1999) and EF (Austin et al., 2001, Degl’Innocenti et al., 1998, Fossati 
et al., 1999, Grant et al., 2001, Porter et al., 2003), and intellectual abilities have been 
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reported to be spared (Austin et al., 2001). There is still no general consensus of a 
specific neurocognitive profile for either unipolar major depression or schizophrenia, 
although several studies have compared the neuropsychological patterns of the two 
diagnostic groups (Egeland et al., 2003, Fossati et al., 1999, Goldberg et al., 1993, 
Merriam et al., 1999). While deficits are seen in several neurocognitive domains in 
unipolar major depression, executive deficits associated with frontal lobe dysfunction 
seem to be particularly prominent (Austin et al., 2001, Elliott, 1998, Veiel, 1997).  
 
Regarding the severity of the dysfunction in depressed patients, some studies have 
indicated that major depressed patients perform at the same level as controls on 
neurocognitive tests (Grant et al., 2001), whereas others have compared their level of 
performance to that of patients with traumatic brain-damage (Veiel, 1997). 
Nevertheless, differences are most often reported to be within the range of from minus 
one half to minus one standard deviation (Lampe et al., 2004, Landrø et al., 2001b). 
Neuropsychological studies find performance in patients with major depression or 
schizophrenia below that of healthy controls, with schizophrenic patients consistently 
performing at lower levels than patients with major depression (Goldberg et al., 1993, 
Merriam et al., 1999). There also seems to be an inter-individual variation in severity 
of neurocognitive impairment in both major depression and schizophrenia, with some 
patients performing in the impaired and some in the non-impaired range (Palmer et al., 
1997, Veiel, 1997). The question concerning how many unipolar major depressed 
patients are neurocognitively healthy is rarely discussed.   
 
Executive functions in unipolar major depression 
There is a general understanding of the presence and importance of superior control 
functions, but still there are numerous terms for these functions such as “executive 
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functions”, “executive processing”, “dysexecutive control”, “frontal functions”, 
“supervisory functions”, “central executive” and many more (Landrø et al., 2001a, 
Logan, 2000, Stuss and Alexander, 2000). In the present thesis these higher order 
functions will be referred to as EF because this term is probably more often used in the 
literature. Some authors have viewed EF as a unitary function, but mostly several 
subfunctions or components have been described within the concept of EF (Lezak, 
1995, Stuss and Alexander, 2000). There are several definitions of EF. In clinical 
studies, the concept is not often defined, but is rather described as results on tests 
thought to measure aspects of EF (Degl’Innocenti et al., 1998, Fossati et al., 1999, 
Grant et al., 2001, Merriam et al., 1999). Tests used to assess EF have either been 
shown to be impaired by frontal lesions or to exemplify a theoretical account of EF, or 
both (Pennington and Ozonoff, 1996). Lower performance on tests of EF can result 
from damage in the frontal lobes and damage in other brain areas (Stuss and 
Alexander, 2000).  
 
In the present thesis EF is defined as higher order cognitive functions involved in 
complex, self-serving, intentional behaviour that control, integrate, organise, inhibit or 
maintain other cognitive functions, i.e. attention, memory and language functions 
(Bryan and Luszcz, 2000, Lezak, 1995, Pennington and Ozonoff, 1996, Pohjasvaara et 
al 2002). Further, the concept of EF has been defined and operationalised as a set of 
different components. Pennington and Ozonoff have described these components as 
abilities of set-shifting, planning, inhibition, working memory and fluency (Pennington 
and Ozonoff, 1996). The components of EF have been operationalised by using 
neuropsychological tests that are recognized as being able to measure these 
subfunctions. Some of these tests are used in studies of depressed samples. 
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Impaired EF can disrupt the ability to perform complex daily life skills, and may 
influence the personal, social, occupational or educational lives of patients with 
damage to the frontal lobes (Griegsby et al., 1998, Manchester et al., 2004, McGurk 
and Mueser, 2003).  
 
In general, most previous studies investigating EF in MDD have included samples of 
patients with either first episode of depression or a mixture of single and recurrent 
episodes of major depression. There is a lack of neurocognitive studies investigating 
EF in homogeneous samples of recurrent MDD patients to obtain high statistical 
power. Deficits in EF have been found in patients with MDD on a group level (Austin 
et al., 2001, Degl’Innocenti et al., 1998, Fossati et al., 1999, Grant et al., 2000, 
Merriam et al., 1999). It remains a question whether there is a significant group 
difference between patients with recurrent depression and healthy controls on measures 
of EF. In addition, there is a lack of information regarding the pattern and severity of 
executive dysfunctions in these patients.  
 
Even if a group difference is found, it is uncertain if all patients with recurrent MDD 
show EF deficits or if this is found in a sub-group only. In patients with schizophrenia, 
the level of performance varies across patients, with a substantial proportion of them 
performing as neuropsychologically normal as their healthy peers (Palmer et al., 1998). 
In general, there is a lack of studies that identify patients with MDD who are 
neuropsychologically normal, and in particular studies that identify and characterize 
patients without impaired EF. A recent report from a study of patients with unipolar 
depression indicated that EF impairment predicted non-response to fluoxetine, and it 
was suggested that EF assessment in depressed patients could “play a particular role in 
the pre-treatment identification of subjects likely to respond to specific medications” 
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(Dunkin et al., 2000). It is also possible that normal performance on EF can be a 
positive prognostic factor in patients with major depression as suggested for patients 
with schizophrenia (Palmer et al.,1998). Thus, it is important to identify the frequency 
and characteristics of patients with recurrent MDD without EF impairment.  
 
Mental disorders as categorical or dimensional conditions 
Different diagnostic categories or subtypes have been investigated to search for 
specific neurocognitive profiles as exemplified in the above section. Still, there is no 
general understanding of a specific profile for unipolar major depression or 
schizophrenia (or for any other mental disorder). Often quantitative performance 
differences between diagnostic groups have been reported, which reflects not only 
different levels of neurocognitive dysfunction but perhaps also different Levels of 
General Psychopathology (LGP). Therefore, it is interesting to explore whether 
executive dysfunctioning is associated with diagnostic category or with LGP. If 
executive dysfunctioning is more strongly related to LGP than to diagnosis, this can be 
taken as support for the continuum hypothesis in psychiatry.  
 
The categorical approach is perhaps the most common in psychiatry, but psychiatric 
syndromes may be more dimensional than categorical by nature. First, there is a range 
of psychiatric symptoms in the population, and the same symptoms can be found in 
different syndromes (overlap). Many people have a mixture of symptoms indicative of 
the co-existence of several syndromes at the same time (co-morbidity). All levels of 
psychiatric symptoms are found in the population from none to high. There is also 
great variability in symptomatology and severity from patient to patient with the same 
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disorder. Additionally, over time there seems to be a shift between psychiatric 
diagnoses.  
 
The discussion of whether mental disorders are categorical or dimensional conditions 
is old, but has been actualised by the ongoing work with the fifth version of DSM and 
an increasing focus on the short comings of the categorical approach for both clinical 
practice and research (Cuthbert, 2005, Krueger et al., 2005, Kupfer, 2005, Lunbeck, 
1999, Widiger and Samuel, 2005). In clinical research, an ideal has been to include 
diagnostic homogenous groups of patients, patients that all have the same mental 
disorder or subtype of the disorder, and preferably none or few confusing co-morbid 
disorders. In clinical practise, clinicians must decide who is sufficiently ill to justify 
treatment and communicate with other clinicians. It is therefore necessary for them to 
use categorical concepts of mental disorders. Some of the problems connected with 
these categorical classification systems are: 1) the systems are consensus-based and not 
evidence-based, 2) the systems have extensive co-morbidity and overlap problems 
attached to them, 3) the systems produce an increasing number of mental disorders due 
to diagnostic splitting and 4) the systems have a problem with “sub threshold cases” 
(Lunbeck, 1999, Widiger and Samuel, 2005). Improved classification systems based on 
new findings from research in genetics, basic neurology and pathophysiology have 
been suggested (Hyman, 2002, Sher, 2000). On this basis, clinical research should 
probably include groups of patients with broader ranges of psychiatric 
symptomatology.  
 
Recently, there has been a growing interest in the dimensional approach in psychiatry 
(Cuthbert, 2005). A psychiatric continuum ranging from bipolar disorders to 
schizophrenia, based on findings from genetic, biochemical and pharmacological 
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studies, has been depicted (Möller, 2003). New perspectives on mental disorders as 
dimensions have also been proposed, and it is possible that the DSM-V will have 
dimensional elements included (Cuthbert, 2005). Lately, studies designed to “integrate 
spectrum and dimensional approaches in addition to categorical ones” have been 
requested (Kupfer and Frank, 2003).  
 
To the best of our knowledge, there is a lack of neuropsychological studies of patients 
with mental disorders that explore the continuum hypothesis/dimensional approach. 
Using this model, it can be argued that MDD and schizophrenia represent different 
levels of psychopathology along the same continuum. There is also empirical evidence 
that supports this view. Firstly, it has been shown that patients originally diagnosed 
with MDD were later re-diagnosed with bipolar disorder and sometimes schizophrenia 
(Chen et al., 1998). Secondly, there is no general understanding of a specific 
neurocognitive profile for MDD or for schizophrenia, though mostly quantitative but 
also qualitative differences between the groups have been suggested (Egeland et al., 
2003, Fossati et al., 1999, Franke et al., 1999, Goldberg et al., 1993, Merriam et al., 
1999). Thirdly, EF impairment is reported in both MDD and schizophrenia, with the 
latter patient group consistently performing at lower levels (Austin et al., 2001, 
Degl’Innocenti et al., 1998, Fossati et al., 1999, Grant et al., 2000, Merriam et al., 
1999). It is therefore still a question if and how LGP is associated with level of EF.  
 
The neurobiology of unipolar major depression 
Different neurochemical systems may interfere in unipolar major depression, and 
abnormalities have been found within the serotonergic, dopaminergic and 
noradrenergic systems. Two main neurobiological systems or circuitries have been 
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proposed for the pathogenesis of unipolar major depression as well as for EF, namely 
the frontal-subcortical systems and the Hypothalamic-Pituitary-Adrenal (HPA-) axis. 
Several psychopharmacological agents affecting these systems can be used to 
effectively treat unipolar major depression.    
Frontal-subcortical systems   
The depressive symptoms have been associated with dysfunction of the prefrontal 
cortex and frontal-subcortical circuitries, but so has impairment of EF (Elliott, 1998, 
Goodwin, 1997, Mayberg, 2000, Mega and Cummings, 1994, Royall, 1999). Results 
from functional brain imaging studies have confirmed decreased blood flow and 
glucose metabolism in the resting state in prefrontal cortex and the subcortical 
structures striatum, pallidum and thalamus (Drevets et al., 1992, George et al., 1994, 
Mayberg, 2000, Videbech, 2000). From a clinical point of view, lesions in any of these 
structures can give similar behavioural consequences. Cognitive activation studies are 
less conclusive, but indicate that depression is associated with an activation level in 
frontal and prefrontal regions that is different from what is found in normal controls 
(Kennedy et al., 1997). Recurrent unipolar major depression has recently been 
associated with volume loss of the same structures as mentioned above, and repeated 
episodes of hypercortisolism has been suggested as one possible aetiological 
mechanism (Sheline, 2000). In schizophrenic patients, a reduced frontal activation 
(hypofrontality) is often reported in functional neuroimaging studies, a finding that is 
also often reported in patients with major depression (Mayberg, 2003, Weinberger and 
Berman, 1996). 
The cortisol hypothesis 
Recurrent unipolar major depression is associated with elevated levels of cortisol, a 
stress hormone that may cause neuron loss (O’Brien, 1997, Sapolsky, 2000, Sheline, 
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2000). Whether neurocognitive deficits in general and specifically EF deficits found in 
depressed patients with recurrent episodes are associated with hypercortisolemia, is 
still unknown.  
 
Under normal conditions the HPA-axis carries out an appropriate acute response to 
stress. There is an endocrine cascade-reaction starting with the hypothalamus, 
continuing to the pituitary, and ending with the secretion of cortisol from the adrenal 
gland. Negative feedback loops then operate at each of these levels to bring forth 
normal homeostasis. Major depression can be viewed as a condition that puts the body 
in a state of chronic stress, and this causes alterations in the HPA-axis with elevated 
levels of cortisol as a result (Kaplan et al., 1994, Sheline, 2000).   
 
Hypercortisolemia is not found in all patients with depression (De Kloet, 2003). 
Chronically and acutely elevated levels of cortisol have been associated with memory 
dysfunctions in major depressed patients (De Quervain et al., 2003, Sauro et al., 2003). 
However, it is unclear whether level of cortisol is also associated with level of EF. If 
such an association can be found, it may help explain why some depressed patients are 
EF impaired whilst others are not. Results from both animal and human studies have 
shown that prolonged high levels of cortisol are neurotoxic (Wolkowitz et al., 2001). 
Studies on humans have found evidence of hippocampal volume loss in long-term 
corticosteroid therapy patients (Sherwood Brown et al., 2004). And it has been shown 
that hippocampal volume loss in women with recurrent depression was predicted by 
duration of depression (Sheline et al., 1999). In summary, it is uncertain if and how 
level of EF performance is correlated with level of cortisol.     
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Aims of the study  
The main aim of the study was to investigate the association between recurrent MDD 
and EF. One objective was to explore whether recurrent MDD patients perform below 
healthy controls on components of EF (Paper I). Another aim was to examine whether 
all patients with recurrent MDD show EF impairment (Paper II). From the angle of 
investigating the predictive value of LGP (including patients with schizophrenia) and 
diagnosis on EF, the continuum hypothesis was explored (Paper III). Finally, the 
cortisol hypothesis was tested by looking at level of saliva cortisol and whether it is 
correlated with level of neurocognitive function, especially EF in recurrent MDD 
(Paper IV). 
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Methods and material 
Research design 
The present thesis is a clinical cross-sectional study performed on two groups of 
patients (recurrent MDD versus schizophrenia) and a healthy control group.  
Subjects 
The subjects included in the present study were recruited from and examined at five 
different psychiatric hospitals/clinics in Oslo and Bergen, Norway. The inclusion 
criteria were: 1) a primary DSM-IV diagnosis of unipolar major depressive episode, 
recurrent type or schizophrenia, not secondary to an organic or substance abuse 
disorder, and a minimum score of 18 on both the Hamilton Depression Rating Scale 
and the Montgomery-Åsberg Depression Rating Scale for the depressed patients, 2) 
age between 20 and 50, 3) written informed consent to participate in the study, 4) 
Norwegian language and 5) normal vision and hearing. The exclusion criteria were: 1) 
a history of head trauma, neurological disorder or developmental dysfunction, 2) 
present alcohol or substance abuse, 3) other medical conditions likely to affect 
neurocognitive functions and 4) recent Electro Convulsive Therapy (ECT).  
Patient samples  
Originally, N=50 patients with unipolar major depressive episode, recurrent type 
(recurrent MDD) according to DSM-IV were included in the BOP. All patients had 
suffered from a minimum of two life-time episodes of major depression, ranging from 
two to five episodes. At inclusion, five depressed patients had psychotic features. The 
depressed patients were moderately to severely depressed, scoring a minimum of 21 
points on the MADRS (Montgomery and Åsberg, 1979), 10 items and 18 points on the 
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Hamilton Depression Rating Scale (HDRS), 17 items (Table 1) (Hamilton, 1960). 
Forty-six patients were taking psychotropic medication, and of these 28 used Selective 
Serotonin Re-uptake Inhibitors (SSRIs) and none used tricyclic antidepressant 
medication. As additional medication, 11 patients were taking small doses of 
neuroleptics (typical neuroleptics: 7, atypical: 3, both: 1). In the present thesis, 
different sub-samples of the original BOP-sample of patients with recurrent MDD are 
studied (Table 1). From the original BOP-sample of N=50 recurrent MDD patients, 
five were excluded due to psychotic symptoms (Paper I), and two for missing data on 
tests assessing EF (Papers II and III). In paper IV, only the N=26 patients who 
delivered a saliva cortisol sample were studied. In Papers I, II and IV, the recurrent 
MDD patients are compared with healthy controls, and in paper III to schizophrenic 
patients.  
 
Table 1: Demographic and clinical characteristics of the recurrent MDD samples 
Characteristics BOP-sample 
Mean (SD) 
Paper I sample 
Mean (SD) 
Papers II & III sample 
Mean (SD) 
Paper IV sample 
Mean (SD) 
Number  50 45 43 26 
Age (years) 35.1 (8.7) 35.6 (8.4) 35.3 (8.4) 35.8 (8.9) 
Gender (M:F) 21:29 18:27 16:27 8:18 
Education (years) 13.9 (2.9) 13.7 (2.8) 13.8 (2.7) 13.4 (2.5) 
HDRS total 22.4 (4.3) 22.4 (4.4) 22.5 (4.5) 21.4 (2.9) 
MADRS total 28.5 (4.4) 28.8 (4.4) 28.8 (4.5) 27.7 (4.1) 
BPRS-E total 43.5 (7.3) 43.0 (8.8) 43.2 (6.6) 42.1 (4.5) 
GAF total 45.9 (8.4) 46.5 (8.8) 46.7 (8.8) 45.5 (8.0) 
Abbreviations: HDRS = Hamilton Depression Rating Scale, MADRS = Montgomery-Åsberg 
Depression Rating Scale, BPRS-E = Brief Psychiatric Rating Scale-Expanded, GAF = Global 
Assesment of Functioning Scale from SCID-I 
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In paper III, a group of patients with schizophrenia (N=53) according to DSM-IV was 
also included. The mean Positive And Negative Syndrome Scale (PANSS) score for 
this group was 75.5 (Key et al., 1987). From this original BOP-sample of 
schizophrenic patients, six were excluded due to missing data on either variables of 
intellectual abilities, EF or LGP, giving the total sum of N=47 schizophrenic patients in 
the present study (paper III). There was one patient with catatonic type, three with 
disorganised type, 37 patients with paranoid type, two with residual type and four with 
undifferentiated type. The majority of the schizophrenic patients were on second 
generation atypical antipsychotic medication.  
Control group 
The control group was recruited through advertisements in the local paper and the 
community and through personal networks. The control group was not significantly 
different from the original BOP-samples of depressed and schizophrenic patients 
regarding age, gender, education, handedness and intellectual abilities. Control subjects 
had no previous psychiatric difficulties. For further information about background 
data, please consult Papers I-IV.   
 
Methods of measurement 
Clinical evaluation and psychometric instruments 
The clinical psychiatric evaluation was individually performed by five trained 
psychiatrists. The inter-rater reliability was estimated according to the procedure 
described in the paper by Egeland et al. (2003), and the average measure Intra-Class 
Correlations (ICC) were found to be over 0.80 for the rating scales used in this study.  
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The patients were diagnosed with the Structured Clinical Interview for DSM-IV Axis I 
Disorders, version 2.0 (SCID-I) (First et al., 1995). Severity of depression was 
estimated by the 17-item HDRS and the 10-item MADRS. Daily psychological, social 
and occupational functioning of the patients was assessed with the Global Assessment 
of Functioning scale (GAF) from SCID-I (First et al. 1995). LGP of the patients was 
measured by the Brief Psychiatric Rating Scale, Expanded version (BPRS-E) (Lukoff 
and Ventura, 1986). In addition, the PANSS was used on both depressed and 
schizophrenic patients. The General Psychopathology subscale (PANSS-G) of the 
PANSS instrument was, together with BPRS-E, used as composite scale of LGP (Paper 
III). BPRS-E is widely used in the evaluation of level of symptoms in different 
psychiatric patient groups and also in schizophrenia and mood disorders. The PANSS 
was mainly developed to assess symptom levels in schizophrenic patients but has also 
been previously included in studies of depressed patients (Galynker et al., 2000).  
Neuropsychological assessment 
The neuropsychological test battery was administered to the patients within three days 
after the clinical psychiatric evaluation. The neuropsychological test battery used in 
BOP included tests assessing several neurocognitive domains: attention, memory, 
psychomotor functions, EF and intellectual abilities. The neuropsychological tests were 
administered by a licensed clinical neuropsychologists, a graduate psychology student 
or by a medical doctor (Kirsten Irene Stordal) supervised by a neuropsychologists. 
Examiners attempted to obtain maximal performance. The subjects were tested 
individually. The time taken to complete the test battery was approximately 4 hours. 
Subjects were allowed breaks between the tests as needed. All subjects had at least one 
break with test administration typically divided into 1.5 to 2 hours sessions.  
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Operationalisation of executive functions 
The neuropsychological tests used to assess EF in this thesis were selected according to 
the following criteria: 1) the tests had been used as EF tests in earlier studies of 
depressed patients and 2) the tests were described as measures of EF components, 
mainly as specified by Pennington and Ozonoff (Pennington and Ozonoff, 1996). The 
six tests included are as follows: Controlled Oral Word Association Test (COWAT) 
(Benton and Hamsher, 1989), Tower of London (ToL) (Krikorian et al., 1994, Shallice, 
1982), Paced Auditory Serial Addition Test (PASAT) (Gronwall, 1977) and the Digits 
Span Backward (DB) subtest from WAIS-R (Wechsler, 1981), Stroop Colour and 
Word Test (Stroop) (Mitrushina et al., 1999, Stroop, 1935) and Wisconsin Card 
Sorting Test (WCST) (Heaton et al., 1993). All tests were administrated and scored 
according to the test manuals.  
 
Other neuropsychological tests  
In addition, the California Verbal Learning Test (CVLT) (Delis et al., 1987) was used 
to assess memory function in paper IV, and the California Computerised Assessment 
Package (CalCAP) (Miller, 1993) together with Stroop were used to measure 
psychomotor function in Papers I and IV. The Victoria Symptom Validity Test 
(VSVT) was included to screen for non-optimal performance during testing and for 
detecting biased or random responding (Slick et al., 1997). Low performance can also 
be associated with motivation problems. Intellectual abilities were assessed with the 
Picture Completion (PC) and Similarities (SIM) subtests from Wechsler Adult 
Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981). For an overview of the 
neuropsychological tests and measures used and neurocognitive components assessed, 
see Table 2 on page 40.  
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Saliva cortisol   
The depressed patients were asked for a saliva cortisol sample at 08.00 a.m. on the 
morning of the day that the neuropsychological testing took place. Measurement of 
saliva cortisol is generally recognised as a better measure of active cortisol in the body 
compared to serum cortisol (Vining et al., 1983). Subjects were instructed to give the 
sample before drinking, eating, smoking or brushing their teeth. Only a morning 
sample was collected in the present study. The samples were deep frozen until the 
moment of analysis. Thereafter, the samples were analysed by radioimmunoassay 
technique with a commercial kit (coat-a-count; Diagnostic Products Corporation, Los 
Angeles, CA, USA) that had an intra-assay variation coefficient between 1.2 and 5.3% 
and a detection limit of 0.2 mg/dl. Saliva cortisol has been found to be highly 
correlated with serum and plasma levels, is largely unbound and represents the free, 
biologically active fraction of cortisol (glucocorticoid hormone) (Vining and 
McGinley, 1986). 
  
 
 
 
 
 
 
 
 
 
 
 40
Table 2: The neuropsychological tests, measures of neurocognitive function and 
neurocognitive components assessed 
 
Domains  Neuropsychological 
tests 
Measures/Scores Components 
WCST Failure to maintain set 
Categories completed 
Perseverative errors 
Set-maintenance 
Set-shifting 
Set-shifting   
Stroop Colour Word Inhibition 
COWAT Phonemic verbal 
fluency 
Categorical verbal 
fluency 
Verbal fluency 
PASAT 3- and 2-sec. inter 
stimulus intervals 
Working memory 
DB Number correctly 
reorganised sequences 
Working memory 
Executive functions  
ToL Number of trials 
completed 
Planning  
SIM Number of correct 
answers 
Verbal abilities, 
Abstraction 
Intellectual abilities  
PC Number of correct 
answers 
Visual analysis, 
Concentration 
Memory  CVLT Acquisition 
Long Delay Free Recall 
Recognition 
Storage  
Retrieval 
 
CalCAP SiRT 
CRT 
SeqRT1 
SeqRT2 
Psychomotor speed Psychomotor functions  
Stroop Word 
Colour  
Psychomotor speed 
Validity test VSVT 5-sec. task Motivation 
 
Abbreviations: WCST= Wisconsin Card Sorting Test, Stroop= Stroop Colour and Word test, COWAT= 
Controlled Oral Word Association Test, PASAT= Paced Auditory Serial Addition Test, DB= Digit Span 
Backwards, ToL= Tower of London, SIM= Similarities from WAIS-R, PC= Picture Completion from 
WAIS-R, CVLT= California Verbal Learning Test, CalCAP= California Computerised Assessment 
Package, VSVT= Victoria Symptom Validity Test.  
 
Statistical analyses 
For Papers I-IV, SPSS for Windows 11.0 was used for statistical analyses. Significance 
levels of p‹0.05 or p‹0.01 and 1- tailed (where we did not expect the depressed subjects 
to perform better than the healthy controls) or 2- tailed levels are reported for each test 
measure. Results from the different neuropsychological tests used were not directly 
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comparable with one another, and in order to make comparisons necessary for 
evaluating cognitive impairment, the different test scores were converted into a scale 
with identical units. In this thesis, the normal distribution based on the mean and the 
standard deviation unit (SD) (Lezak, 1995) and standardized scores (z-scores) were 
used.   
 
In Paper I, multivariate linear regression analyses were conducted to explore inter-
group differences. The first regression model included a depression measure as 
predictor variable and each EF measure as dependent variable. In the next steps, 
demographic variables, psychoactive medication and psychomotor speed was adjusted 
for as possible confounding factors. Inter-group differences were also illustrated using 
z-scores, and a reliability analysis (alpha) was performed for all EF measures together 
and a composite score was made based on the mean of z-scores for these 10 EF 
measures. 
 
In Paper II, z-scores were calculated for the set-maintenance, inhibition, verbal fluency 
and working memory measures to obtain a dimensional EF summary score. Since a 
Cronbach’s coefficient alpha of 0.701 was found for the z-scores calculated from these 
four EF measures, the scores were summarised. EF unimpairment was defined from 
the distribution of EF scores in the control group and as performance above -1.0 SD. 
To be defined as impaired on working memory, both the PASAT and the DB scores 
had to be impaired. Choen’s d was used as an effect-size measure (Rosnow, Rosenthal 
and Rubin 2000). To explore associations between demographic/clinical characteristics 
and EF impairment, linear and categorical analyses were performed using Pearsons’ 
correlation and Student t-test/Pearson Chi-square test, respectively. A multivariate 
regression model was used to explore the interaction between 
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demographics/intellectual abilities and diagnosis (dichotomous variable indicating 
depression or non-depression) in the prediction of EF impairment. In this model the EF 
summary score was treated as a dependent variable (i.e. level of EF impairment = 
diagnosis + age + age x diagnosis). Demographic and intellectual abilities variables 
were used as independent variables.  
 
In Paper III, a dimensional LGP measure was calculated by using the sum scores of 
both BPRS-E and PANSS-G because both measures together gave higher effect sizes 
than each one alone in the statistical analyses. For the depressed and schizophrenic 
patients together, N=90, z-scores were calculated for each of these measures. A 
Cronbach’s coefficient alpha of .94 was found for the z-scores of BPRS-E and 
PANSS-G, and therefore these scores were summarised. As for the operationalisation 
of a dimensional EF measure, z-scores were calculated for set-maintenance, inhibition, 
verbal fluency and working memory measures for the depressed and schizophrenic 
patients together (N=90). A Cronbach’s coefficient alpha of 0.61 was found for the z-
scores calculated from the four EF measures, and likewise the results from these scores 
were summarised. Multiple linear regression models were performed and all were 
adjusted for age and gender.  
 
In Paper IV, z-scores were calculated for the neurocognitive measures of the depressed 
patients based on the performance of the control group. Inter-group differences were 
explored by ANOVA analyses. Associations between clinical, biological, intellectual 
ability and cognitive measures were explored using Pearsons’ correlation coefficient r. 
Partial correlations were performed in order to investigate possible confounding 
factors.   
 43
Ethical aspects 
The study was approved by the Regional Committee for Medical Research Ethics. All 
participants provided written informed consent to participate in the study. There were 
no risks or suffering connected with participation. The patients received treatment for 
their existing condition, both psychotherapy and antidepressant 
medication/neuroleptics as well as additional medication. Due to suffering and suicide 
risk it would be highly unethical to ask patients to stop taking their antidepressant 
medication in order to participate in the study. The extensive neuropsychological test 
battery could for some patients, both depressed and schizophrenic be hard to endure, 
but they were encouraged to take as many breaks as they needed. For some patients it 
was necessary to finish the battery the following day. A few patients, especially in the 
schizophrenic group, did not manage to complete the whole battery and were registered 
with missing data for some of the tests or subtests. In order to reduce possible 
suffering, the patients were asked to deliver saliva cortisol samples instead of blood 
samples. The results from the neuropsychological evaluation where given to the 
psychiatrist/psychologist of the patients, so the information could be used for 
rehabilitation purposes.  
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Results  
Summary of results from Papers I-IV 
Paper I 
In the part of the study reported in paper I, a set of neuropsychological tests was used 
to measure different components of EF to assess if patients with recurrent MDD 
performed below healthy controls and to study characteristics of the pattern and 
severity of this EF dysfunction. The group of patients with recurrent MDD (N=45) 
consistently performed below the healthy control group on the EF measures. 
Significant group differences were found for eight of the 10 EF measures assessed. 
These were measures of verbal fluency, inhibition, working memory and set-
maintenance and set-shifting. There was no significant group difference for planning as 
measured by ToL. The group difference was still significant for all components except 
for set-shifting after adjusting for additional medication and psychomotor retardation. 
The severity of the executive dysfunction was within –1.0 SD from the control group 
mean for each of the 10 EF measures. For the composite EF z-score, severity was 
calculated to -0.22 SD.   
Paper II 
In paper II, the aim of paper I was extended by posing questions such as: Is impairment 
of EF a general finding in recurrent MDD? What are the characteristics of depressed 
patients with unimpaired EF? The depressed subjects (N=43) were assessed with the 
same neuropsychological tests as in paper I except for ToL, which was not used here. 
According to the definition of EF unimpairment as determined from the distribution of 
the control group, 56 % of the recurrent MDD patients were defined as EF unimpaired. 
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Altogether 16 % of the healthy controls were defined as EF impaired. An odds ratio of 
4.2 (95 % C.I. from 1.6-10.9) indicated that the risk of EF impairment was about four 
times higher in recurrent MDD patients than in healthy controls. Another finding was 
that 90 % of the variance in EF could be explained by other factors than being 
depressed. The depressed patients without EF impairment were characterised by fewer 
depression episodes and higher intellectual abilities than patients with EF impairment, 
but the groups were not significantly different on measures of symptomatology, 
general psychopathology and global functioning.  
Paper III 
In this part of the study, employing data including patients with recurrent MDD and 
schizophrenia (N=90), it was examined whether the variance in EF is related to 
psychiatric diagnosis or to LGP. The EF tests used were similar to those used in Paper 
II. LGP explained more of the variance (14.4 %) in EF than did diagnosis (9.7 %). 
Correspondingly, the standardised regression coefficients (betas) were stronger in LGP 
than in diagnosis. LGP predicted only about 25 % of the effect of diagnosis on EF. In 
other words, most of the effect of diagnosis on EF could not be attributed to LGP. 
Diagnosis explained about 15 % of the effect of LGP on EF. Thus, most of the effect of 
LGP on EF could not be attributed to diagnosis. It was shown that approximately 5 % 
of the variance in EF could be explained by diagnosis, when LGP was already included 
in the model. It was also shown that approximately 10 % of the variance in EF could 
be explained by LGP, when diagnosis was already included in the model. To sum up, 
LGP has a stronger independent effect on EF and explains more additional variance in 
EF in addition to diagnosis than vice versa.  
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Paper IV 
In the final part of the study reported in Paper IV, a neurobiological correlate (saliva 
cortisol) was included. It was asked if EF was correlated with saliva cortisol in patients 
with recurrent MDD (N=26) and how. As measures of EF, failure to maintain set from 
WCST and Stroop colour-word subtask were included. Also, psychomotor speed 
(CalCAP and Stroop) and memory measures (CVLT) were included in this study. It 
was found that level of saliva cortisol was significantly and inversely correlated with 
EF and retrieval from CVLT. Another finding was that depressive symptomatology 
(measured by HDRS and MADRS) was significantly and inversely correlated with 
psychomotor speed. In other words, an elevated level of saliva cortisol was associated 
with EF dysfunction as well as with a post-encoding memory deficit, but not with 
psychomotor retardation in recurrent MDD.  
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Discussion and conclusion 
Synopsis of results 
The study shows that a group of moderately to severely depressed patients with 
recurrent MDD has mild dysfunction across EF components compared with a healthy 
control group. The following EF components are statistically significantly affected in 
recurrent MDD: verbal fluency, inhibition, set-maintenance and working memory. Set-
shifting and planning seem to be spared. Despite that patients with recurrent MDD on a 
group basis perform below healthy controls on several components of EF, more than 
half of the patients can be classified as EF unimpaired when the definition of 
unimpairment is based on the performance of the control group. The unimpaired 
subgroup is characterised by fewer depression episodes and higher intellectual abilities 
than the impaired subgroup, but the subgroups are not significantly different regarding 
symptomatology, general psychopathology and global functioning. Further, LGP 
explains more of the variance in EF than does diagnosis (recurrent MDD or 
schizophrenia), though diagnosis independently explains some of the variance. Finally, 
level of saliva cortisol is inversely correlated with performance on measures of EF in 
recurrent MDD.   
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Results in view of previous findings 
The association between recurrent unipolar major depression and executive 
functions 
A significant group difference between patients and healthy controls 
The study confirms earlier findings that patients with MDD on a group basis show EF 
impairment when in the symptomatic phase, but also confirms depressed patients’ 
complaints of neurocognitive problems as well as psychiatrists’ or psychologists’ 
observations of such in depressed patients. In general, there is a lack of neurocognitive 
studies, which restrict samples to MDD patients with recurrent episodes. Therefore, 
results from the present study are compared with findings from earlier studies of 1) 
currently depressed patients with MDD, including patients with a mixture of recurrent 
and first episode(s) of depression, and 2) recurrent MDD patients with no or mild 
current depressive symptomatology.  
 
In the present study, a statistically significant group difference was found for measures 
of EF between patients with moderate to severe, recurrent MDD and healthy controls. 
This finding is in line with most previous studies (Degl’Innocenti et al., 1998, Grant et 
al., 2001, Landrø et al., 2001b, Porter et al., 2003). Porter et al. (2003) found a group 
difference on EF measures between unmedicated patients with MDD and controls. 
Two recent papers have investigated EF in samples of patients with recurrent episodes, 
and both have confirmed that patients with recurrent MDD perform below healthy 
controls on measures of EF, even when in the euthymic phase (Lampe et al., 2004, 
Paelecke-Habermann et al., 2005). Paelecke-Habermann and colleagues (2005) found 
that MDD patients in the euthymic phase with three or more depression episodes 
showed a lower performance on measures of EF compared to patients with one to two 
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episodes. In the present study, a group difference was also found between patients with 
recurrent MDD and schizophrenia for EF measures, a finding in line with most 
previous studies (Fossati et al., 1999, Goldberg et al., 1993, Merriam et al., 1999, Rund 
et al., 2006), but not all (Franke et al., 1993). The result that executive dysfunctions co-
occur with recurrent MDD (but also with schizophrenia) therefore seems to be a strong 
finding. 
 
A mild dysfunction across components of executive functions 
Another finding in the present study was that the executive dysfunctions were mild in 
recurrent MDD when evaluating group differences in effect sizes. This finding may 
have clinical implications. Statistically significant dysfunctions were found for verbal 
fluency, inhibition, set-maintenance and working memory. There were no significant 
group differences between patients and controls for set-shifting after controlling for 
psychomotor speed and additional psychotropic medication. Planning abilities, as 
measured by a version of ToL, were also spared. However, the non-significant finding 
for planning is possibly due to good a ceiling effect. The version of the ToL test used 
was too easy for both patients and controls resulting in good test performance in both 
groups. Previously, preserved planning abilities in out-patients, mainly first episode 
MDD patients, have been reported (Porter et al., 2003), although deficits have been 
shown in other studies (DeBattista, 2005). Verbal fluency dysfunction has consistently 
been reported in studies of MDD, even in unmedicated patients (Degl’Innocenti et al., 
1998, Fossati et al., 1999, Landrø et al., 2001b, Porter et al., 2003, Veiel, 1997), yet 
contradictory findings also have been reported (Grant et al., 2001). Regarding the 
presence of a dysfunction in inhibition, some studies support this finding (Lampe et al., 
2004, Paelecke-Habermann et al., 2005), while others do not (Degl’Innocenti et al., 
1998). Two meta-analyses have also confirmed inhibition problems in MDD (Veiel, 
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1997, Zakzanis et al., 1999). Zakzanis et al. (1999) suggested that this could be caused 
by reduced psychomotor speed. In the present study, reduced psychomotor speed was 
controlled for in the statistical analysis, but still an inhibition dysfunction was present 
in recurrent MDD. The results of the present study are in contrast to most previous 
findings for set-maintenance and set-shifting as well. In a review by Austin and 
colleagues (2001) a selective set-shifting deficit was suggested for patients with MDD, 
though the results of the present study can not support this. As for set-maintenance, 
Grant and co-workers (2001) also reported a low performance on failure to maintain 
set from WCST. This is of interest because most often this parameter is not affected in 
patients with MDD (Degl’Innocenti et al., 1998, Merriam et al., 1999). Regarding 
working memory, dysfunction of this EF component has been reported in other studies 
of MDD (Landrø et al., 2001b, Paelecke-Habermann et al., 2005, Porter et al., 2003). A 
recent review has highlighted deficits in working memory as central in MDD 
(DeBattista, 2005).  
 
These differences in results across studies of MDD regarding which EF components 
are affected or spared may be due to methodological problems. One problem is 
differences in operationalisation of EF. Another problem is including a homogeneous 
sample of MDD patients. The heterogeneity of unipolar major depression (psychotic 
vs. non-psychotic, recurrent vs. first-episode) (Lampe et al., 2004, Porter et al., 2003, 
Schatzberg et al., 2000), the medication status (with or without psychotropic 
medication) (Lampe et al., 2004, Porter et al., 2003) and the status of depressed 
patients (hospitalised or out-patients) (Degl’Innocenti et al., 1998, Elliott, 1998, Grant 
et al., 2001) may contribute to the lack of reliable findings regarding EF deficits. 
Differences in age and severity of depression of MDD samples are other factors that 
have been suggested to explain inconsistency in findings (Austin, 2001, Elliott, 1998).  
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The present study confirms that mild EF dysfunctions are associated with recurrent 
MDD. The performance of the depressed patients on measures of verbal fluency, 
inhibition, set-maintenance and working memory was within 1.0 SD of the sample 
mean below the controls. For the EF summary score, the group difference between 
depressed patients and controls was calculated to 0.22 SD of the sample mean in 
favour of the controls. There are previous studies that have also used the z-score format 
in severity calculations of neurocognitive deficits in MDD (Lampe et al., 2004, Landrø 
et al., 2001b, Reischies and Neu, 2000). Investigating euthymic or mildly depressed 
female recurrent MDD patients, Lampe et al. (2004) found a slightly more severe result 
on a composite EF score (based on measures from Stroop and WCST) with these 
patients performing 0.65 SD of the sample mean below the control group. It is possible 
that this group difference would have been larger if the patient group had been 
moderately to severely depressed like our sample. Landrø and colleagues (2001b) 
found even more severe effect sizes for both working memory and verbal fluency, but 
still within approximately 1.25 SD of the sample mean in favour of controls in a group 
of mainly female recurrent MDD patients. Reischies and Neu (2000) found effect sizes 
in MDD patients that ranged within 0.5 to 1.0 SD from the sample mean below the 
control group for measures of verbal fluency, memory and psychomotor speed. Based 
on the reported effect sizes between EF and depression, it seems reasonable to 
conclude that the severity of the dysfunction is mild in recurrent MDD on a group 
basis.  
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Do all patients with recurrent unipolar major depression have executive 
dysfunctions? 
Many recurrently depressed patients have unimpaired executive functions  
Though recurrent MDD patients on a group basis consistently show executive 
dysfunctions, the present study showed that more than 50 % have unimpaired EF when 
unimpairment was defined as performance above -1.0 SD of the sample mean of the 
control group on more than one component of EF. The unimpaired subgroup of 
recurrent depressed patients was characterised by higher intellectual abilities and fewer 
depression episodes. In comparison, 16 % of the controls were classified as EF 
impaired when impairment was defined as performance equal to or below -1.0 SD in 
the control group on more than one component of EF. A similar study of schizophrenic 
patients and neuropsychological functioning found that nearly one third was classified 
as neuropsychologically normal, whereas 15 % of the controls were impaired on 
neurocognitive functions (Palmer et al., 1997). Our study only assessed one 
neurocognitive domain, EF. In the study by Palmer et al. (1997) several neurocognitive 
domains were investigated but the prevalence of impairment in the healthy control 
group in this study was comparable to the prevalence found in the present study. It is 
also reasonable that EF impairment is present in a subgroup of healthy controls. The 
results confirm findings from other studies of the existence of groups of unipolar major 
depressed patients with normal or nearly normal EF (Grant et al., 2001, Purcell et al., 
1997). 
 
In the present study, 44 % of patients with recurrent MDD were defined as EF 
impaired. The choice of cut-off for impairment of neurocognitive functions varies 
across studies; as does the EF variables studied. Thus, it is difficult to directly compare 
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this result to the results from other studies. A study using the 5th percentile as cut-off, 
found that about 37 % of a group of major depressed patients, some with recurrent 
depression, performed below a matched control group on a measure of verbal fluency 
(Reischies and Neu, 2000). In a meta-analysis, 11 % of the MDD samples scored 2 SD 
or below the control group mean on measures of verbal fluency (COWAT), whereas 
50.2% scored equal to or below the cut-off on measures of mental flexibility and 
control (Trail Making Test part B and Stroop colour-word subtest) (Veiel, 1997). In a 
recent study by Rund et al. (2006), investigating the schizophrenic and recurrent MDD 
patients from BOP, 25 % of depressed patients scored more than 1.5 SD below the 
mean of the control group on measures of working memory and psychomotor speed. In 
sum, there is a large heterogeneity within MDD patients regarding EF with some 
patients performing in the normal range and some in the impaired range.  
 
The EF unimpaired subgroup had suffered from fewer depression episodes than the 
impaired subgroup. The finding gives support to the model of recurrent MDD 
involving repeated episodes of hypercortisolism causing structural changes affecting 
fronto-subcortical systems (Sheline et al., 1999, Sheline et al., 2000). Therefore, it is 
possible that patients with recurrent MDD but with fewer episodes will have less EF 
impairment compared with patients who have experienced more depression episodes. 
Another finding was that EF unimpairment was associated with higher intellectual 
abilities as measured by PC and SIM from WAIS-R. Is it possible that we measure IQ 
rather than EF? This raises the question about how EF are related to IQ, and 
specifically how the different components of EF relates to IQ. Recently, it was shown 
that both WAIS-R and Wechsler Intelligence Scale for Children-Reviced IQ measures 
are differentially correlated with different EF components (inhibition, set-shifting and 
set-maintenance, updating working memory, verbal fluency), though mostly low and 
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non-significant correlations were found (Ardila et al., 2000, Friedman et al., 2006). An 
interesting result of the present study is that 35 % recurrent MDD patients showed no 
EF impairment at all. These patients have a recurring brain dysfunction, and yet show 
no dysfunction in EF. One possible explanation for this finding is that these patients 
may have had above average EF before the start of the MDD. Due to problems with the 
low sensitivity and ecologic validity associated with the tests, it is possible that some 
patients within the unimpaired group still may have real-life executive dysfunctions 
(Manchester et al., 2004). Thus, it appears that there are true but small differences 
between EF normal and EF impaired recurrent MDD patients.  
 
The present study may perhaps be criticised for the choice of EF tests and 
unimpairment definitions. Currently, there is no general understanding of how this 
should be done and there are many examples of other definitions and 
operationalisations; differences are even found within the BOP (Degl’Innocenti et al., 
1998, Egeland et al., 2003, Fossati et al., 1999, Grant et al., 2001, Landrø et al., 2001, 
Merriam et al., 1999, Palmer et al., 1997, Rund et al., 2006). Further research will be 
needed to determine whether the differences in EF represent differences in either 
clinical subtypes of MDD, degrees of illness or premorbid level of functioning. Still, 
the identification of MDD subgroups with regards to present or absent EF impairment 
will be important because the two groups may have different treatment needs 
(DeBattista, 2005, Dunkin et al. 2000, Mohlman, 2005, Palmer et al., 1997, Rund et al., 
2006). 
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Are executive dysfunctions associated with diagnosis or level of psychopathology?   
Exploring the continuum hypothesis of psychiatric disorders 
Despite that EF deficits consistently have been reported in MDD patients including the 
present results, it can be argued that the association between recurrent MDD and EF is 
rather weak. Two results from the study support this: The finding that 90 % of the 
variance in EF was explained by other factors than depression, and the result that more 
than 50 % of the depressed patients were EF unimpaired (Paper II). Findings reported 
elsewhere as depicted in the introduction section may lead to speculation if general 
factors other than the depression itself can not explain the variance in EF.  
 
In the present study it was found that LGP as measured by BPRS-E and PANSS-G 
explained more of the variance in EF than the diagnosis of MDD (or schizophrenia). 
Diagnosis also explained some, though less, of the variance. Rephrasing the result, the 
study shows that a variable (general psychopathology) common across mental 
disorders (though imperfectly illustrated by only two diagnoses) explains more of EF 
than the specific diagnostic categories do (MDD versus schizophrenia). It can therefore 
be assumed that the shared symptomatology of mental disorders is more important for 
the understanding of neurocognitive functioning (as illustrated by EF) than their 
differences represented by conventional categorical diagnoses. This finding is in line 
with the continuum hypothesis of psychiatry, and also supports clinical intuition that 
mental disorders probably are dimensional rather than categorical conditions. That a 
dimensional approach explains more of EF than a categorical approach is interesting 
because this research field has mostly been engaged in investigating specific diagnostic 
groups and subgroups of psychiatric patients on measures of neurocognitive function. 
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In sum, there seems to be more similarities than differences between MDD and 
schizophrenia regarding EF.  
 
The present study put restrictions on both symptomatology and severity of illness. In 
the planning phase of the study we though that it would be a strength of the study to 
include homogeneous patient groups, but as the work progressed and we became 
increasingly engaged in the dimensional approach to mental disorders this actually 
proved problematic. Ideally, patient groups with intermediate diagnoses (i.e. psychotic 
depression, schizoaffective disorder, and bipolar disorder as well as other mental 
disorders) and all severity levels could have been included. In addition, healthy 
controls could also have been included. On the other hand, because the included patient 
groups were homogenous and thus, limiting the variance, it could be argued that the 
results are even stronger. Also, there is the possibility that the findings could have been 
caused by a statistical phenomenon. It is generally more difficult to achieve statistically 
significant correlations between categorical variables (which reduce variance) and a 
dimensional out-come measure (EF) than with dimensional variables. In light of this, 
the finding that EF is more associated with LGP than with diagnosis needs to be 
replicated in future studies.  
 
The results of this study are in line with previous neuropsychological studies claiming 
that there are quantitative differences between MDD and schizophrenia regarding 
neurocognitive function in general and specifically EF (Goldberg et al., 1993, Fossati 
et al., 1999, Franke et al., 1993). But the findings are also in line with studies finding 
qualitative differences between the two diagnostic groups (Goldberg et al., 1993, Rund 
et al., 2006). In a recent study by Rund and co-workers (2006), the recurrent MDD 
patients and schizophrenic patients were qualitatively different regarding 
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neurocognitive profiles. By using diagnostic classifications we may be prevented from 
understanding aspects of psychiatric disorders that are relevant to EF. This finding 
partly favours the continuum hypothesis in psychiatry and partly the conventional 
diagnostic classification.  
 
Thus, EF deficits are not specific for MDD since such deficits are present in 
schizophrenia as well as other mental disorders (Stein et al., 2002, van den Heuvel et 
al., 2005). In a review by Schillerstrom et al. (2005) it was shown that EF impairment 
has also been found in diverse medical diseases such as vascular disease, hypertension, 
respiratory and cardiac illnesses, HIV, diabetes, renal failure and neoplastic illness 
after controlling for comorbid psychiatric illness.  
 
The present study showed that level of psychopathology explained EF more than 
diagnosis. Another more creative extrapolation from this finding is that the level of 
pathology explains EF. Perhaps EF impairment reflects a more universal effect of 
being severely ill. In Maslow’s hierarchy of needs (Maslow, 1954) the premise is that 
unless an individual’s basic needs have been met, higher levels in the pyramid such as 
self-realisation are of no relevance because survival is the most basic human 
component. Drawing a parallel to this idea, we can imagine that as long as the body is 
ill and needs to heal, higher order intellectual processes may become a luxury that the 
body cannot afford.  
 
The present study supports the inclusion of dimensional approaches in coming 
diagnostic classification systems. Future research of EF in mental disorders should 
perhaps include dimensional measures to increase the variance in psychiatric 
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symptomatology and to avoid problems with co-morbidity, diagnostic overlap and 
overemphasising effects of diagnosis.  
The association between executive functions and saliva cortisol in recurrent 
unipolar major depression  
In the present study two results provide indirect support to the cortisol hypothesis and 
the assumption that repeated depression episodes with elevated levels of cortisol can 
cause progressive brain damage in frontal-subcortical systems. The results are also in 
favour of the assumption that executive dysfunctions in recurrent MDD are linked to 
the same postulated progressive brain damage. Firstly, an association between higher 
saliva cortisol levels and lower EF was found in the recurrent MDD patients (Paper 
IV). Secondly, the recurrent MDD subgroup with EF impairment had experienced a 
higher number of depression episodes than the subgroup with normal EF (Paper II). 
Thus, recurrent MDD seems to be associated with elevated cortisol, which again may 
be associated with executive dysfunctions. It also seems that the more depression 
episodes (with a probable elevated level of cortisol) a patient has suffered the higher 
the possibility of EF impairment.      
 
It can be argued that the association between saliva cortisol and EF probably is 
stronger than shown in the present study. The finding of an inverse association 
between saliva cortisol and EF in this study is weaker than it actually is because only 
one morning saliva cortisol sample was collected. This is a limitation of the present 
study that can lower validity. Today, due to present knowledge of irregular diurnal 
patterns of cortisol secretion in MDD, the collection of several saliva samples are 
recommended, but one sample was not uncommon at the time that we included our 
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depressed patients (Odber et al., 1998, Peeters et al., 2004). In the correlation analyses 
in paper IV multiple comparisons were made with the possibility of Type I errors.  
 
Despite these limitations, the results of the present study may be indicative of that 
executive dysfunctions in recurrent MDD can be attributed to cortisol hypersecretion. 
As reported elsewhere, hypercortisolemia is well documented in MDD but found only 
in about half of the patients (De Kloet, 2003). Both chronically elevated cortisol level 
and increases due to stress or experimental injections have been associated with 
memory deficits (De Quervain et al., 2003, Sauro et al., 2003, Young et al., 2001). A 
recent study reported that higher cortisol levels were associated with higher numbers of 
depression episodes in unipolar major depression (Sher et al., 2004). Together, this 
evidence may be one explanation for why only half of the recurrent MDD patients 
were EF impaired.  
Possible functional consequences of mild executive dysfunctions  
Though mild, it is possible that dysfunctions in several EF components will have 
functional and clinical consequences for patients with recurrent MDD. The literature 
on the association between depression-related executive dysfunctioning and functional 
disability is sparse. It is known that functioning deteriorates by actual depressive 
symptomatology (Spijker et al., 2004), and it can be speculated about to what extent 
co-occurring executive dysfunctions will further reduce functioning. In a study of 
elderly people, EF determined functional status for both self-reported and observed 
activities of daily living (Grigsby et al., 1998). In geriatric non-demented patients with 
current or a history of MDD, executive dysfunctions were associated with reduced 
ability to shop, prepare meals, take medicine (compliance) and manage money 
(Kiosses and Alexopoulos, 2005). In patients with frontal lobe damage, executive 
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dysfunctions may compromise independent living and disrupt the patients’ personal 
and social lives and their abilities to work or attend school (Manchester et al., 2004). 
The severity of executive dysfunctions is probably higher in the patient groups 
mentioned above compared to our patient sample, but the functional effects might be 
similar, though of a milder type. Conversely, it can be assumed that normalisation of 
executive dysfunctions will improve general functioning.  
 
Recently, studies have referred to clinical and treatment issues concerning executive 
dysfunctions in patients with MDD. Regarding outcome, EF has been suggested to be a 
predictor of treatment outcome in both adult and elderly MDD patients (Dunkin et al., 
2000, Mohlman, 2005). Dunkin et al. (2000) found that executive dysfunctions in 
MDD predicted lack of response to pharmacotherapy (fluoxetine). MDD is associated 
with an increased risk of suicide, and recently deficits in EF were associated with 
suicidal ideation (Marzuk et al., 2005). Very few studies have investigated beneficial 
effects of psychopharmacological treatment on executive dysfunctions in MDD. 
However, some agents have been suggested, i.e. SSRIs (sertraline), noradrenergic 
agents, dopamine enhancing agents, modafinil and antiglucocorticoids (Constant et al., 
2005, DeBattista, 2005). In addition to psychopharmacological treatment, a specific 
type of psychotherapy may be effective. It has been shown that in elderly MDD 
patients with executive dysfunctions, psychotherapy (problem-solving therapy) was 
more effective on reducing both depressive symptomatology, functional disability and 
executive dysfunctions than supportive therapy, though normal levels for EF were not 
attained (Alexopoulos et al., 2003). Also, exercise has been shown to improve 
executive dysfunctions in adults with MDD (Kubesch et al., 2003). For rehabilitation, 
tailored EF compensatory techniques have been suggested for MDD patients (Kiosses 
and Alexopoulos, 2005). It has also been suggested that EF are neurocognitive 
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functions that must be taken into account to ensure occupational success in patients 
with severe mental disorders, including MDD (McGurk and Mueser, 2003). 
 
Traditional executive tests have been criticised for not being “direct evidence for the 
existence or nature of basic operations of frontal systems” and for having low 
relevance for everyday life (Alexander and Stuss, 2006, Manchester et al., 2004). At 
present, there seems to be two main trends evolving with regards to the development of 
tests of EF. The first aims at developing tests with increased construct validity; these 
are intended to measure the actual brain functions involved in EF (Alexander and 
Stuss, 2006). The second aims at increasing the ecological validity by making 
executive tests that reflect real world functioning (Manchester et al., 2004). 
Comparative information on how patients function neurocognitively as well as 
behavioural observations of how patients perform when carrying out a structured task 
in a real-life setting have been suggested for EF evaluations of patients (Alexander and 
Stuss, 2006, Manchester et al., 2004). In summary, executive dysfunctions may be an 
extra burden to the functional disabilities associated with recurrent MDD. It is 
important to identify such neurocognitive deficits in MDD for optimal treatment, 
counselling and rehabilitation.  
Speculations regarding the pathogenesis of executive dysfunctions in unipolar 
major depression  
Due to the design of the present study it is only possible to speculate about where in 
the brain executive dysfunctions are situated. The results from this study show that 
patients with recurrent MDD have deficits in verbal fluency, inhibition, set-
maintenance and working memory. Results from functional neuroimaging studies 
investigating activation patterns in MDD patients while patients are performing 
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neuropsychological tasks assessing these EF components have shown the following: 
verbal fluency is associated with the dorsolateral prefrontal cortex, inhibition is 
associated with the anterior cingulate and dorsolateral prefrontal cortex and working 
memory is associated with lateral prefrontal cortex and anterior cingulate (Frith et al., 
1991, Rose et al., 2005, Wagner et al., 2006). No functional neuroimaging studies 
have, to the best of my knowledge, reported activation patterns related to deficits of 
failure to maintain set from WCST in MDD, but a meta-analysis concluded that the 
WCST could be viewed as an attention-demanding executive task due to fronto-
parietal activation patterns (Buchsbaum et al., 2005). In a functional Magnetic 
Resonance Imaging (fMRI) study investigating 12 of the recurrent MDD patients 
included in the present study on a variant of the PASAT task, brain activation was 
shown in the frontal lobes (right inferior and middle frontal gyrus) (Hugdahl et al., 
2004). In addition, reduced psychomotor speed was observed in the recurrent 
depressed patients of the present study, a finding that has been associated with the 
striatum (Degl’Innocenti et al., 1998). Functional neuroimaging studies investigating 
recurrent MDD patients have shown a reduced hippocampal volume (Sheline et al., 
1999, Neumeister et al., 2005). Thus, the EF pattern of recurrent MDD is compatible 
with dysfunctions of frontal-subcortical circuitries that also have been associated with 
depressive symptomatology. The “hypofrontality” hypothesis of unipolar major 
depression is still strong, but now there is evidence from functional neuroimaging 
studies that have shown increased frontal activation associated with depression (for a 
review see Surguladze et al., 2003).       
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General methodological issues 
Medication effects on executive functions   
An overview of antidepressants and additional medication used by the participating 
subjects at the time of neuropsychological testing is given in the methods section and 
in Papers I-IV. In the present study we did not have adequate control over medication 
effects, and this is a limitation of the study. Despite that investigation of medication 
effects on EF was not a scope of the present study, it is important to keep in mind that 
medication effects are a possible confounding factor. In an un-medicated sample of 
recurrent MDD patients, the performance on tests of EF may have been lower. In the 
literature, findings are inconclusive with respect to the effects of antidepressant 
medication on neurocognitive functions in general (Amado-Boccara et al., 1995). 
However, modern antidepressant medication, SSRIs and monoamine oxidase 
inhibitors, are known to have less negative or even positive effects on neurocognitive 
functions compared with older tricyclic antidepressant medication, which due to 
anticholinergic and antihistaminergic properties have sedative effects affecting 
psychomotor speed (Amado-Boccara et al., 1995, Elliott, 1998). In the present study, 
all patients were taking newer types of antidepressants (mainly SSRIs). However, 
previous studies assessing EF in medication free MDD patients, have also detected 
significant associations between depression and lower performance on measures of EF 
(Grant et al., 2001, Porter et al., 2003). Although we could not rule out the effects of 
medication in the present study, additional medication (benzodiazepines and/or 
antipsychotic medication) was adjusted for in the statistical analyses of Papers I and 
IV, and this did not change the main results of these papers. Long-time use of 
benzodiazepines seems to be associated with impairment in neurocognitive functions 
(Golombok et al., 1988). As for antipsychotics, either used as additional medication in 
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recurrent MDD or as main medication in schizophrenia, Mohamed et al. (1999) found 
no significant differences in neurocognitive performance in medicated or un-medicated 
patients with schizophrenia. Others have shown that atypical antipsychotics may even 
have beneficial effects on neurocognitive functions (Purdon, 2001). It is therefore 
unlikely that the EF dysfunction in recurrent MDD can be strongly related to 
medication use, although we cannot rule out medication as a possible confounding 
factor.  
Measurement of psychiatric symptomatology 
In the present study only conventional diagnostic and psychometric instruments were 
used. Patients were diagnosed by the SCID-I at inclusion by trained psychiatrists. 
Though imperfect, the diagnostic criteria in the DSM-IV are consensus-based and 
under revision. The level of depressive symptomatology, general psychopathology and 
global functioning was measured by “gold standards”, i.e. frequently used, and well 
validated continuous scales (HDRS, MADRS, PANSS, BPRS and GAF). For research 
purposes, these conventional instruments make it relatively easy to compare samples of 
depressed patients across neurocognitive studies.           
Measurement of neurocognitive functions and particularly executive functions 
Neuropsychological assessment has been concerned with delineating isolated 
components of cognitive functioning using standardised tests administered under 
laboratory conditions. There is a rich selection of standardised single tests available 
that can be used to assess EF or the separate components. The neuropsychological test 
battery constructed for the BOP-study was based on theory, tradition and prior 
experience with the tests. It mainly included often used and well validated tests 
assessing different cognitive domains such as attention, memory function, 
psychomotor function and EF. There were two exceptions. They were experimental 
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neuropsychological tests called the Backward Masking and Dichotic Listening, but 
these were not included in the papers of this thesis. In the present thesis, the tests 
acknowledged to assess EF, which by definition are demanding and complex tasks, 
were selected because they had been used as EF tests in previous studies of depressed 
patients and because the tests had been described as measures of components of EF 
(Pennington and Ozonoff, 1991). The neuropsychological testing was performed by 
trained test-technicians under standardised “laboratory” conditions. In this thesis, 
neuropsychological operationalisation was based on either theoretical foundations (i.e. 
Pennington and Ozonoff, 1991) and/or estimates of internal reliability within 
dimensions. The view that different tests or test measures are indicators of different 
aspects of cognitive functions can be problematic because there is substantial 
overlapping across test measures and cognitive domains (Lezak, 1995, Zakzanis et al., 
1999). In addition, many neuropsychological tests are multi-factorial, especially if the 
tests are “complex” (Stuss and Alexander, 2000). Another aspect is the sensitivity and 
specificity of EF tests as tests that are sensitive may not be specific and vice versa. The 
EF tests used in the present thesis are generally recognized as sensitive to frontal lobe 
damage, although evidence exists that these tests sometimes can be insensitive to even 
large lesions of the frontal lobes (Manchester et al., 2004). It is also important to keep 
in mind that the relationship between EF (a psychological construct) and the functional 
anatomy of the frontal lobes, and probably also other brain regions, is not completely 
understood (Stuss and Alexander, 2000). Neuropsychological research supplemented 
with functional and structural neuroimaging techniques can therefore be useful in 
extrapolating deficits of EF deficits to the functional anatomy of the brain. Since 
neuropsychological tests vary from study to study, uni-factorial tests are rare, and the 
operationalisation of EF is difficult. This makes it more difficult to compare the 
performance of depressed samples across neuropsychological studies. 
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Reliability considerations and underestimation of strength  
The higher the reliability of measures in a study, the easier it will be to demonstrate 
real group differences and associations. On the contrary, lower reliability will reduce 
the effect size or strength of associations, but will never give false positive findings. In 
the present thesis, the reliability varies. Regarding the diagnostic instrument, rating 
scales and neuropsychological tests these were most often “gold standard” instruments 
and therefore the potential reliability is assumed to be high. The five raters that 
determined diagnoses and severity of illness were trained psychiatrists that were 
informed that the inter-rater reliability were to be calculated for the scaled instruments. 
Five cases were selected, and the inter-rater reliability was calculated for HDRS, 
MADRS, PANSS, BPRS and GAF. Average measure ICC was over 0.80 for all rating 
scales. For the diagnoses, consensus was reached for selected cases during clinical 
discussion and no diagnostic disagreement was found. For other measures included in 
the study, i.e. the saliva cortisol measure, duration of illness and number of depression 
episodes and some demographic variables, the reliability may have been lower. 
Regarding the administration of the neuropsychological tests, there were altogether 
three test technicians. The tests were administered under standardised conditions 
according to the test manuals, and test protocols were used that contained the 
information/text that was read aloud to the subjects during testing. But unfortunately, 
no ICC was calculated for the test technicians, and though this is not often done within 
this research field, this could be considered a limitation with the present study. Due to 
the fact that several tests are computerised, it is not always a useful procedure. A 
substantial variance was found for the depression, EF and saliva cortisol measures 
(Papers I-IV). But when the measurement of interest is highly variable, large samples 
are needed to get reliable results (Altman, 1991). In the analyses of data, it was mainly 
summary scores that were calculated, although single measures were also used. To 
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produce composite scores or summary scores of EF, single measures were reliability 
tested and summarised when high internal consistency was found. As a consequence of 
reliability being moderate to high, the risk of underestimating the strength of 
associations is rather low.   
Power considerations and Type II errors 
The size of the sample is important to obtain statistically significant results. The 
significance level, the sample size, the strength of the association, and the power 
constitute a closed system in that three of the parameters can determine the fourth 
(Altman, 1991). In the planning phase of BOP, the total number of patients and 
controls that had to be included to secure sufficient power was calculated from 
neuropsychological data from earlier studies on older depressed patients. Since 
younger, better functioning depressed patients were included in the study, and due to 
missing data, this resulted in a loss in power. In the present study the sample size is 
small or marginal in statistical terms, although it could be argued that it is relatively 
large as compared to studies within the same research tradition. An implication of a 
marginal power for Papers I-IV is reduced possibility of finding significant results and 
accordingly an increased risk of false negative results (Type II error) (Altman, 1991). 
One way of combating low power is to reduce the total number of single test measures 
by calculating summary scores. Therefore, in Paper III composite scores were 
calculated for both psychopathology and EF. Summary scores for EF were also 
calculated in Papers I and II. This will increase the reliability and the strength of the 
association as well as the statistical power.  
 
When performance of a clinical group on a particular neuropsychological test or 
measure is found to be significantly different from that of a non-clinical group, this 
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finding is often used to support the view that the test or measure is able to differentiate 
between the groups. However, it is important to keep in mind that statistical 
significance only reflects the likelihood or probability of a particular finding being 
observed by chance. It neither reflects the size of differences between groups, nor if 
every individual of the clinical group is affected or only some, nor does it indicate if 
the test or measure can discriminate participants with sufficient accuracy for clinical 
use. In Paper IV, multiple comparisons were performed between the clinical, 
neuropsychological and saliva cortisol variables and several statistically significant 
results on the 0.05 level were reported. Performing multiple comparisons increases the 
risk of false positive results (Type I error) (Altman, 1991). Multiple comparisons were 
also performed in Papers I and II. To avoid the risk of false positive findings, post hoc 
adjustment, i.e. by the Bonferroni method could have been performed. The Bonferroni 
method is recognised as a conservative method, and applying this adjustment on our 
results would most certainly have led to mostly non-significant findings. On the other 
hand, this conservatism also increases the risk of losing true associations between 
variables. In conclusion, the increase in reliability achieved by computing summary 
scores should be regarded as favourable compared to using multiple test measures 
because the hypothesis is tested only once. However, in Paper I where one of the aims 
was to investigate the profile of EF in recurrently depressed individuals, multiple 
single test measures had to be used. Analyses on single test measures can therefore be 
useful provided that the statistical power is sufficiently high. In addition to 
significance, it is also important to evaluate confidence intervals. For the present thesis, 
confidence intervals could have been reported more often. 
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Generalisation of findings 
To decide whether the findings can be applied to the population of interest, namely 
people with unipolar major depression, it must be determined as to whether the sample 
is representative of this population in the first place. The multi-centre design of the 
study gave access to mainly hospitalised patients or patients with a history of 
hospitalisation. Some of the patients at the point of inclusion were recruited from out-
patient clinics. A minority (and mainly in the depressed group) of the out-patients had 
not been hospitalised earlier.  
 
The sample of patients with recurrent MDD that was included in the present study is 
representative for this population, and the results can therefore be generalised to this 
group of patients. For the depressed group only recurrently depressed patients were 
included, yet this is the most prevalent type of the disorder in the population (Angst, 
1999, Mueller, 1999). By doing so, we anticipated that the recurrently depressed 
sample would be more cognitively impaired compared to first-time depressed samples 
or a mix of the two, but in fact they were comparably neurocognitively impaired to 
other studies. Of course, directly comparing our results to that of other studies is not 
entirely safe as the studies may be different regarding design, sample, measures, etc., 
but still we allowed our selves to do this. The patients were moderately to severely 
depressed according to the depression scales, and therefore more severely depressed 
than samples in some studies, but not others (Degl’Innocenti et al., 1998, Landrø et al., 
1997, Purcell et al., 1997). The decision of not including patients with milder 
depression restricts findings to more severe forms of depression. Patients with 
psychotic features or bipolar disorder were excluded together with those who satisfied 
other exclusion criteria set for all subjects. Thus, the depressed patient group represents 
an intermediate group regarding level of psychopathology load. In conclusion, the 
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findings of the present study can be generalised to unipolar major depressed patients 
but probably to a lesser degree to milder, older or first-time or never hospitalised 
depressed patient groups.    
 
The control group subjects were recruited through newspaper and community 
advertisements, but also from personal networks. Among 50 control subjects it is 
possible that some had milder psychiatric symptomatology and non-severe organic 
brain damage that can influence the performance on neuropsychological tests. The 
controls were not administered the psychiatric psychometric instruments, and this is a 
limitation of the study. In addition, the majority of subjects within the control group 
were working. This is not representative to the general population. This also implies 
that their cognitive functioning was better than a control group that contained a larger 
proportion of unemployed or long term sick-leave subjects, which increases group 
differences.  
 
It can be argued that both the depressed and the schizophrenic groups are 
homogeneous groups (which was also an explicit aim of the BOP); while these limited 
groups increase the power of the study they also limit the generalisation of findings. In 
conclusion, the inclusion criteria of the study probably restricts generalisation more 
than the exclusion criteria.   
Research design 
It is important that the research design suites the objectives of the study. Sometimes it 
is obvious what the best design is, but more often there are several reasonable ways of 
designing a study (Altman, 1991). The cross-sectional design was chosen in the present 
study. This is a commonly used design because it is inexpensive and easy to conduct. 
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In the present study, the first aim was to investigate between-group differences 
regarding EF. Perhaps the better research design for this aim (Paper I) was in fact the 
cross-sectional design we used, although in hindsight increased power is desirable. A 
longitudinal design would have been an alternative for the second aim (Paper II) where 
it is questioned if all depressed patients are impaired in EF. For the third aim, the 
cross-sectional design was appropriate in the search for other explanations than 
diagnosis of the variance in EF (Paper III). Optimally though, for this aim the 
depressed and schizophrenic patient samples included should have been more 
heterogeneous in regards to severity of illness. Additional patients with psychotic 
depression, bipolar disorder, schizoaffective disorder and healthy control subjects 
should also have been included so that the sample reflected many symptoms belonging 
to the psychiatric continuum. For the fourth aim, the cross-sectional design was 
appropriate for studying associations between saliva cortisol level and level of 
neurocognitive function (Paper IV). Another option would have been to use a 
longitudinal design allowing inferences to be made on the causality of the associations, 
although longitudinal designs also have shortcomings. To sum up, the cross-sectional 
design was optimal for the specific aims of this thesis, but for other objectives such as 
causality or “trait or state” issues, longitudinal designs would have been the preferred 
research design.  
 
Biases and possible confounding factors 
Selection and volunteer biases  
Selection biases may have been present for all papers included in this thesis. Depressed 
and schizophrenic patients complaining about cognitive problems may systematically 
have been referred more often to the study by their psychiatrist or psychologist than 
patients without such complaints. If so, inflation in effect sizes for differences between 
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depressed patients and healthy controls may have occurred in the present study. 
Another potential bias that goes in the opposite direction is that when recruiting 
volunteer subjects to participate in a research project there is the possibility that only 
optimally functioning subjects choose to participate. The patients who were referred, 
but chose not to participate were possibly more cognitively impaired and more 
severely ill from their depression or schizophrenia, and this would have reduced effect 
sizes. For the schizophrenic patients there was also a bias towards better cognitively 
functioning paranoid schizophrenic patients, which in Paper III may have led to 
underestimation of effect sizes for the association between level of psychopathology 
and level of EF. The patient samples were based on individuals, who volunteered to 
participate and were not consecutively admitted, a preferred method because this 
would have reduced the possibility of selection bias at this stage of the study. 
Demographic data and health-related data were not collected for the patients who did 
not volunteer. As for the control subjects, these were mainly working and were 
therefore probably healthier, more sociable and more neurocognitively well than the 
depressed patients. Most likely, this selection bias would have led to an inflation of 
effect sizes for differences between depressed patients and healthy controls. In 
conclusion, because biases go in opposite directions the strength of the associations 
found are probably neither inflated nor underestimated.     
 
Possible confounding factors 
In Papers I and II there were no statistically significant group differences between the 
depressed group and the control group for age, gender, education or intellectual 
abilities. In Paper III, there was no group difference for level of education. However, 
there is the possibility that also many other factors or third variables can confound the 
association between depression and EF, i.e. psychotropic medication and other 
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substances, psychomotor speed, intellectual abilities, general functioning, sleep, 
motivation, occupational status, etc. (Kiosses and Alexopoulos, 2005, Lezak, 1995, 
Mortensen et al., 2005, Porter et al., 2003). These confounding factors may exist 
independent of the disorder or may be part of the disease. In Paper I, an effort was 
made to adjust for additional medication and psychomotor speed as possible third 
variables and this adjustment reduced the effect sizes for the association between 
depression and EF by one-third to one-fourth, respectively. In Paper III, age and 
gender was adjusted for in the multiple linear regression models, but not the level of 
intellectual abilities. In Paper IV, the level of intellectual abilities was especially 
controlled for in partial correlations, and this adjustment did not change the fact that a 
statistically significant correlation was found between elevated saliva cortisol and 
executive dysfunction. In schizophrenic patients the mean IQ level is usually below 
that of depressed patients and controls who all have normal IQ. This third variable is 
an important confounding factor between mental disorders and neurocognitive function 
(Lezak, 1995, Mortensen et al., 2005). A test assessing motivational aspects was 
included in the present study, the VSVT, and the results showed normal motivation in 
the depressed group as compared to controls. The matching of the study groups is no 
guarantee for having controlled for all variables that may affect the result. There may 
be other variables that can explain the results and also residual confounding from the 
variables already mentioned. This was not performed in the present papers. No pair-
wise matching or randomisation was performed in the present study. In conclusion, 
there may be possible confounding effects that partially explain some of the findings 
from the present study.  
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Strengths of the study 
As discussed above, the clinical samples were well characterised and homogeneous. 
The SCID-I was used. In addition, the neuropsychological test battery was broader and 
the depressed and schizophrenic samples were relatively well-sized compared to other 
neuropsychological studies on depressed and schizophrenic patients.   
 
Conclusions 
The contributions of the papers in this thesis may be summarised as follows:  
The present study confirms earlier findings as well as patients’ subjective complaints 
and clinicians’ observations that patients with unipolar major depression perform 
below healthy controls on most measures of higher order cognitive functions, EF. This 
is also true for patients that have suffered from two or more recurrent episodes of 
depression. Several components of EF such as verbal fluency, inhibition, set-
maintenance and working memory were affected in the recurrently depressed group 
compared to controls, whereas set-shifting was spared. On a group basis, the executive 
dysfunction was mild in patients with recurrent MDD. 
   
Despite a significant group difference between patients and healthy controls, many 
recurrent MDD patients had unimpaired EF. The subgroup of patients without 
executive dysfunctions was characterised by fewer episodes of depression and higher 
intellectual abilities than patients with EF impairment. It therefore seems that 
increasing numbers of depression episodes are associated with executive 
dysfunctioning whereas higher intellectual abilities are associated with normal EF.  
 
The present thesis also showed that more than 90% of the variance in EF was 
explained by other factors than being depressed. In the search for other explaining 
 75
factors, it was found that LGP explained more of the variance in EF than diagnosis did. 
But diagnosis also had a separate contribution to the variance in EF. The study thus 
partly provides empirical support for the continuum hypothesis in psychiatry, namely 
that different mental disorders can be viewed as different levels of psychopathology. A 
consequence of this model is that dimensional approaches may be applied to mental 
disorders and neurocognitive function in future research as opposed to continuing the 
search for unique neurocognitive profiles for narrower diagnostic groups.  
 
The level of EF was found to be inversely associated with the level of saliva cortisol in 
a smaller sub-sample of patients with recurrent unipolar major depression. Therefore, 
the present study both directly and indirectly supports the cortisol hypothesis.   
 
Clinical implications of findings  
It may be difficult to directly transfer the evidence from a laboratory setting in the 
present study to every day situations. Nevertheless, it can be speculated that the 
findings from the present study may have implications for the clinical investigation, 
management and rehabilitation of patients with recurrent unipolar major depression. 
Clinicians may choose to include a neuropsychological assessment in the clinical 
investigation in order to identify patients with executive dysfunctions and other 
neuropsychological dysfunctions because these patients may have special treatment 
and rehabilitation needs. Evidence elsewhere suggests targeted, 
psychopharmacological and psychotherapeutical treatments for patients with unipolar 
major depression who experience co-occurring executive dysfunctions (Alexopoulos et 
al., 2003, DeBattista, 2005). There are a few indications that executive dysfunctions 
should be a focus in the rehabilitation of unipolar major depressed patients in order to 
improve general functioning and get them back to work (Grigsby et al., 1998, Kiosses 
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and Alexopoulos, 2005, Manchester et al., 2004, McGurk and Mueser, 2003, Spijker et 
al., 2004). It is possible that patients with recurrent major depression who have 
executive dysfunctions, and because of that have problems solving complex tasks, will 
need a longer sick-leave period than patients without executive dysfunctions.    
 
In a more global perspective, the main challenge will still be to diagnose and treat 
patients with unipolar major depression to reduce disability and suffering. For patients 
with recurrent unipolar major depression it is important to effectively treat the acute 
depression episode as well as avoid future episodes. In the future, simple screening 
instruments should be available for physicians in order to detect executive 
dysfunctioning and other neurocognitive dysfunctions in patients with unipolar major 
depression. Also, antidepressant medication should be developed that target executive 
dysfunctioning in patients with unipolar major depression. It will also be important to 
avoid using antidepressants with negative side-effects on neurocognitive functioning. It 
can also be argued that there is a need for a consensus and standardisation within the 
field of neuropsychology regarding the operationalisation of EF as parallel to the 
psychiatric consensus-based diagnostic systems.  
 
 
Suggestions for future research 
The present thesis has shown a need for future studies within this and overlapping 
research fields that:   
1) aim to clarify the concept of EF and the relationship to the functional frontal 
lobe  
2) investigate the functional, treatment or rehabilitation consequences of an 
additional “diagnosis” of executive dysfunctions in patients with unipolar major 
depression  
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3) document effects of antidepressant medications or other agents that are targeted 
towards executive dysfunctioning in unipolar major depression 
4) include dimensional approaches, in addition to categorical approaches, to both 
depressive/psychiatric symptomatology and executive/neurocognitive 
functioning 
5) include possible biological correlates, i.e. cortisol  
6) continue to explore the causality of executive dysfunctions in mental disorders 
including unipolar major depression    
 
In order to perform these investigations, several methods and research designs should 
be combined. In the first review paper of neurocognitive deficits in depression, 
William Miller (1975) concluded: “There is rather widespread agreement regarding the 
clinical description of depression, and there is a considerable amount of research which 
demonstrates that depressives exhibit deficits relative to normals and neurotics on 
intelligence tests and laboratory tasks and in communication. What is most needed now 
are theories of depressive deficits and studies designed to test these theories.” To a 
certain extent this statement is still valid today. Hopefully, future studies will focus on 
the non-uniqueness of neurocognitive deficits in mental disorders and explore the 
continuum way of thinking about mental illness and neurocognitive functions.  
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